Anshul Dhankher, an analyst from LifeSci Capital, maintained the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated price target remains the same with $21.00.
Anshul Dhankher has given his Buy rating due to a combination of factors related to Perspective Therapeutics’ ongoing clinical trials and promising developments. The company has recently dosed the first patient with VMT01 in combination with nivolumab as part of their Phase 1/2a trial for MC1R+ metastatic melanoma, which is a significant milestone. The chosen dose of 1.5 mCi for VMT01 is expected to stimulate the immune system without adversely affecting immune cells infiltrating the tumor, potentially increasing the effectiveness of nivolumab and enhancing its therapeutic impact.
Furthermore, the initial data from the monotherapy arm of the trial has shown promising activity, justifying further investigation at a lower dose. This strategic approach in their trial design, along with the company’s innovative use of MC1R-targeted radioligand therapy, supports the potential for significant advancements in treatment efficacy. These factors collectively contribute to Dhankher’s optimistic outlook and Buy rating for Perspective Therapeutics’ stock.
According to TipRanks, Dhankher is an analyst with an average return of -47.2% and a 0.00% success rate.
In another report released on March 13, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $10.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com